• The Science of ENBREL
  • Experience
  • Proven Efficacy

The Attributes of ENBREL

ENBREL blocks the activity of excess active tumor necrosis factor (TNF) to reduce the inflammation that causes psoriatic lesions and joint pain.

Infections, including serious infections, some fatal, have been observed in patients treated with ENBREL.

Confidence in Experience

Evaluated in clinical studies over the past 19 years in rheumatoid arthritis (RA)1*

  • > 14 years of postmarketing experience in RA since 19981
  • > 8 years of postmarketing experience in moderate to severe plaque PsO since 20041

ENBREL is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis. ENBREL can be initiated in combination with methotrexate (MTX) or used alone.

* Initial clinical research in RA patients began in 1993. ENBREL approved for adult chronic moderate to severe plaque psoriasis in 2004.

Established Efficacy1-4

In adult moderate to severe plaque psoriasis, ENBREL has established efficacy through 24 weeks in a worldwide plaque psoriasis clinical trial.


Support for Patients

"When I talk with the ENBREL Support™ nurses, I feel very comfortable with the information I'm getting. They help me every step of the way."
"The ENBREL Support™ Card helped me continue to afford my treatment."
ENBREL offers you and your patients support you can count on. Discover the wide variety of resources available through ENBREL Support™.

Learn more


 
INDICATIONS

ENBREL is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis. ENBREL can be initiated in combination with methotrexate (MTX) or used alone.

ENBREL is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients ages 2 and older.

ENBREL is indicated for reducing signs and symptoms, inhibiting the progression of structural damage of active arthritis, and improving physical function in patients with psoriatic arthritis. ENBREL can be used in combination with methotrexate in patients who do not respond adequately to methotrexate alone.

ENBREL is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis.

ENBREL is indicated for the treatment of adult patients (18 years or older) with chronic moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Supportive data

Moderate to Severe Plaque Psoriasis
In medical studies, nearly half of patients saw 75% skin clearance in their moderate to severe plaque psoriasis in 3 months with ENBREL. Overall, 3 out of 4 patients saw 50% skin clearance in 3 months. ENBREL can work fast; many patients saw improvement within 2 months. Your results may vary.

Psoriatic Arthritis
In a medical study, ENBREL was shown to be effective in about 50% of psoriatic arthritis patients who used it at 6 months. Clinical responses were apparent at the time of the first visit (4 weeks) and were maintained through 6 months of therapy.

Indications

Plaque Psoriasis
ENBREL is indicated for the treatment of adult patients (18 years or older) with chronic moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Psoriatic Arthritis
ENBREL is indicated for reducing signs and symptoms, inhibiting the progression of structural damage of active arthritis, and improving physical function in patients with psoriatic arthritis. ENBREL can be used in combination with methotrexate in patients who do not respond adequately to methotrexate alone.

Initiate Prior Authorizations

Submit prior authorizations online. Register today for access to ENBREL Prior Auth Assist.

Prescribed by nearly 11,000 dermatology professionals in the US.1‡

1. Data on file, Amgen.

† Dermatologists, nurse practitioners, physician's assistants in dermatology offices, and dermatology subspecialists, which include D, DS, DMP, PDD, and some NP, PA, and IM/PCPs. Based on cumulative data from 2003 through May 2011.

When Brent's plaque psoriasis symptoms worsened, he felt isolated and stopped going out with friends.

Brent asked his doctor about ENBREL.

"I feel more comfortable in my skin."